DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The first product under development, ReViVox™ is based on a clinically validated drug currently approved for a different medical use and route of administration. The novel formulation will manage undesirable side effects resulting from neurotoxin injections in both medical and cosmetic applications.
RiskLD is a physician-led startup out of Cleveland focused on improving maternity outcomes.
Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that...
On July 13, 2021, AngelMD is hosting the Healthcare Impact Investing Summit with a coalition of partners all focused on improving innovation in healthcare....
